Sitamaquine
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000740)
Timeline
Indications
Mechanism of action
- LeishmaniaINHIBITOR
Leishmania inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)CCCCCCNc1cc(OC)cc2c(C)ccnc12- Mol. weight
- 343.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL57004 ↗
Also known as
- 8-((6-(diethylamino)hexyl)amino)-6-methoxy-4-methylquinoline
- 8-(6-diethylaminohexylamino)-6-methoxy-4-methylquinoline dihydrochloride
- 8-aminoquinoline
- 8-aminoquinoline
- 8-aminoquinoline
- 8-quinolinamine
- n,n-diethyl-n'-(6-methoxy-4-methyl-8-quinolinyl)-1,6- hexanediamine
- sitamaquine
- sitamaquine
- sitamaquine
- sitamaquine
- sitamaquine
- wr006026
- wr 006026
- wr-006026
- wr6026
- wr 6026
- wr-6026
- wr-6026
- wr-6026
- wr-6026
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00381394 | Phase 2 | Aug 1, 2006 | GlaxoSmithKline |
| NCT00000740 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000863 | Phase 2 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 2 | 1999 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2006 |
2 organizations
Page 1 / 1